dc.contributor.author | Hall, E | |
dc.contributor.author | Cameron, D | |
dc.contributor.author | Waters, R | |
dc.contributor.author | Barrett-Lee, P | |
dc.contributor.author | Ellis, P | |
dc.contributor.author | Russell, S | |
dc.contributor.author | Bliss, JM | |
dc.contributor.author | Hopwood, P | |
dc.contributor.author | TACT Trial Investigators, | |
dc.date.accessioned | 2020-08-13T11:47:52Z | |
dc.date.issued | 2014-09-01 | |
dc.identifier.citation | European journal of cancer (Oxford, England : 1990), 2014, 50 (14), pp. 2375 - 2389 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3953 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2014.06.007 | |
dc.description.abstract | BACKGROUND: The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a median of 5 years suggested no improvement in disease-free survival with FEC-D. Given differing toxicity profiles of the regimens, the impact on quality of life (QL) was explored. METHODS: Patients from 44 centres completed standardised QL questionnaires before chemotherapy, after cycles 4 and 8, at 9, 12, 18 and 24 months and at 6 years follow-up. Patient diaries assessed frequency, associated distress and impact on daily activity of 15 treatment related side effects. FINDINGS: 830 patients (415 FEC-D; 415 controls) contributed assessments during 0-24 months; 362 of whom participated again at 6 years. During chemotherapy, FEC-D impaired global health/QL and depression rates and significantly more QL domains than standard regimens. Novel diary card ratings highlighted significantly more distress and interference with daily activities due to FEC-D side effects compared with standard treatment. In both groups, most QL parameters returned to baseline levels by 2 years and were unchanged at 6 years. INTERPRETATION: Within expected negative effects of chemotherapy on wide ranging QL domains FEC-D patients reported greater toxicity, disruption and distress during treatment with no improvement in disease outcome at 5 years than patients receiving standard anthracycline-based chemotherapy. Findings should inform future patients of relative costs and benefits of adjuvant chemotherapy. | |
dc.format | Print-Electronic | |
dc.format.extent | 2375 - 2389 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | TACT Trial Investigators | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Taxoids | |
dc.subject | Tamoxifen | |
dc.subject | Cyclophosphamide | |
dc.subject | Fluorouracil | |
dc.subject | Methotrexate | |
dc.subject | Anthracyclines | |
dc.subject | Epirubicin | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Therapeutics | |
dc.subject | Chemotherapy, Adjuvant | |
dc.subject | Quality of Life | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Surveys and Questionnaires | |
dc.subject | United Kingdom | |
dc.subject | Bridged-Ring Compounds | |
dc.title | Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001). | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2014-06-08 | |
rioxxterms.versionofrecord | 10.1016/j.ejca.2014.06.007 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2014-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of cancer (Oxford, England : 1990) | |
pubs.issue | 14 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.publication-status | Published | |
pubs.volume | 50 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | ICR-CTSU Urology and Head and Neck Trials Team | |
dc.contributor.icrauthor | Hall, Emma | |
dc.contributor.icrauthor | Bliss, Judith | |